- •Cladribine tablets are an immune-reconstitution therapy for relapsing MS (RMS).
- •Belgian, single-center, retrospective cohort of 84 cladribine-treated RMS patients.
- •72.6% of included patients retained NEDA-3 at mean follow-up (22.6 months).
- •More events in year 1 for patients with ≥2 prior DMTs and switching from FNG.
- •Valuable real-world insights that might inform treatment decisions.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Interpretation and impact of real-world clinical data for the practicing clinician.Adv. Ther. 2018; 35: 1763-1774https://doi.org/10.1007/s12325-018-0805-y
- A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.Mult. Scler. Relat. Disord. 2021; 52102945https://doi.org/10.1016/j.msard.2021.102945
- Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.Brain. 2019; 142: 2276-2287https://doi.org/10.1093/brain/awz156
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.Mult. Scler. Relat. Disord. 2019; 29: 168-174https://doi.org/10.1016/j.msard.2019.01.038
- Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis.Mult. Scler. Relat. Disord. 2019; 29: 157-167https://doi.org/10.1016/j.msard.2018.11.021
EMA, 2022. Mavenclad (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring. . https://www.ema.europa.eu/en/medicines/dhpc/mavenclad-cladribine-risk-serious-liver-injury-new-recommendations-about-liver-function-monitoring. (Accessed 23/01/2023.
EMA, 2022. Mavenclad : EPAR - Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad. (Accessed 07/10/2022.
- A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 416-426https://doi.org/10.1056/NEJMoa0902533
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.Lancet Neurol. 2011; 10: 329-337https://doi.org/10.1016/S1474-4422(11)70023-0
- Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study.Mult. Scler. 2021; (13524585211049392)https://doi.org/10.1177/13524585211049392
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study.Mult. Scler. 2018; 24: 1594-1604https://doi.org/10.1177/1352458517727603
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.Lancet Neurol. 2014; 13: 257-267https://doi.org/10.1016/s1474-4422(14)70005-5
- Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy.Mult. Scler. 2021; 27: 465-474https://doi.org/10.1177/1352458520921087
- Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.Ther. Adv. Neurol. Disord. 2019; 12 (1756286419887596)https://doi.org/10.1177/1756286419887596
- Cladribine tablets added to IFN-β in active relapsing MS: the ONWARD study.Neurol. Neuroimmunol. Neuroinflamm. 2018; 5 (e477-e477)https://doi.org/10.1212/NXI.0000000000000477
- Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.Ann. Clin. Transl. Neurol. 2020; 7: 2199-2212https://doi.org/10.1002/acn3.51206
- Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.Mult. Scler. Relat. Disord. 2022; 62103812https://doi.org/10.1016/j.msard.2022.103812
- Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).Ther. Adv. Neurol. Disord. 2020; 13 (1756286420922685-1756286420922685)https://doi.org/10.1177/1756286420922685
- Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study.Neurol. Ther. 2022; 11: 1193-1208https://doi.org/10.1007/s40120-022-00364-6
- Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres.Mult. Scler. 2022; 28: 257-268https://doi.org/10.1177/13524585211012227
- Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.Mult. Scler. Relat. Disord. 2022; 61103755https://doi.org/10.1016/j.msard.2022.103755
- Skin reactions in patients with multiple sclerosis receiving cladribine treatment.Neurol. Neuroimmunol. Neuroinflamm. 2021; 8https://doi.org/10.1212/nxi.0000000000000990
- Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study.Mult. Scler. Relat. Disord. 2023; 70https://doi.org/10.1016/j.msard.2022.104491
- Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.Ther. Adv. Neurol. Disord. 2019; 12 (1756286419854986)https://doi.org/10.1177/1756286419854986
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/s1474-4422(17)30470-2
US Department of Health and Human Services, 2022. Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development. CTEP. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. (Accessed 07/11/2022.